Free Design Audit Available - Click Here for Details

CroíValve reports positive first-in-human valve repair data

CroíValve today announced favorable patient outcomes in a first-in-human clinical trial of its Duo tricuspid coaptation valve system.

Professor Wojciech Wojakowski presented data looking at Duo in the treatment of tricuspid regurgitation (TR) at New York Valves 2024.

Duo, a novel, transcatheter coaptation valve, works in tandem with the native tricuspid valve to restore valve function. Delivered using percutaneous techniques, Duo is anchored in a novel way — it is secured across the annulus by a support catheter anchored to a stent in the superior vena cava. This anchor system leaves the right heart and native valve apparatus untouched.

The system won FDA investigational device exemption at the start of the year and kicked off an early feasibility study for the Duo system. Duo could enter the hot tricuspid repair space that features Edwards’ Evoque and Abbott’s TriClip systems.(Read more about Duo’s unique approach at Medical Design & Outsourcing).

Sign up for Blog Updates